Litcius/Paper detail

FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway

Guanglei Chen, Lisha Sun, Xi Gu, Liping Ai, Jie Yang, Zhan Zhang, Pengjie Hou, Yining Wang, Xunyan Ou, Xiaofan Jiang, Xinbo Qiao, Qingtian Ma, Nan Niu, Jinqi Xue, Hao Zhang, Yongliang Yang, Caigang Liu

2023Science China Life Sciences21 citationsDOI

Topics & Concepts

Triple-negative breast cancerHomeobox protein NANOGCancer researchBreast cancerDownregulation and upregulationCell cycleCell cycle checkpointCell growthCyclin D1CancerMedicineBiologyInternal medicineEmbryonic stem cellInduced pluripotent stem cellBiochemistryGeneticsGeneAdvanced Breast Cancer TherapiesCancer-related Molecular PathwaysMicrotubule and mitosis dynamics
FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway | Litcius